Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Celldex Therapeutics, Inc.

Market Cap 2.55B 2.22B 2.06B 1.92B 3.61B 240B 3.63B 24.39B 9.45B 118B 9.56B 9.35B 411B P/E 2026 *
-7.47x
P/E 2027 * -7.42x
Enterprise Value 1.96B 1.71B 1.58B 1.48B 2.78B 185B 2.8B 18.79B 7.28B 91.1B 7.36B 7.2B 316B EV / Sales 2026 *
744x
EV / Sales 2027 * 170x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 2014-07-29
Chief Executive Officer 64 2008-08-31
Director of Finance/CFO 55 2009-03-31
Director TitleAgeSince
Director/Board Member 64 2008-11-30
Chairman 80 2025-06-04
Director/Board Member 93 2008-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.55B
+1.44%+1.71%-10.98%-5.59% 43.13B
+3.31%+5.93%+310.97%+532.23% 34.65B
+2.84%+2.14%+9.34%+45.55% 30.03B
-1.70%-7.54%+8.43%-21.54% 28B
-1.90%-1.56%+10.24%+22.81% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+108.76% 13.14B
-0.57%-2.43%+5.08%+6.76% 12.53B
-0.26%+1.15%+98.13%+79.60% 12.25B
Average +0.41%+0.73%+60.00%+96.07% 23.61B
Weighted average by Cap. +0.77%+1.27%+65.47%+111.07%

Financials

2026 *2027 *
Net sales 2.63M 2.3M 2.13M 1.99M 3.74M 249M 3.76M 25.24M 9.78M 122M 9.89M 9.68M 425M 11.96M 10.43M 9.66M 9.04M 16.96M 1.13B 17.06M 115M 44.41M 556M 44.9M 43.94M 1.93B
Net income -330M -288M -267M -250M -468M -31.14B -471M -3.16B -1.23B -15.33B -1.24B -1.21B -53.23B -370M -323M -299M -280M -525M -34.96B -528M -3.55B -1.38B -17.21B -1.39B -1.36B -59.75B
Net Debt -584M -509M -472M -442M -828M -55.12B -833M -5.6B -2.17B -27.13B -2.19B -2.15B -94.2B -507M -442M -410M -384M -719M -47.88B -724M -4.86B -1.88B -23.57B -1.9B -1.86B -81.83B
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
32.43USD
Average target price
57.53USD
Spread / Average Target
+77.41%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!